Home  »  Companies   »  Read This First Before You Buy Landos Biopharma In...

Read This First Before You Buy Landos Biopharma Inc. (NASDAQ: LABP) Stock

Landos Biopharma Inc. (NASDAQ:LABP) shares, rose in value on Friday, 08/05/22, with the stock price up by 7.96% to the previous day’s close as strong demand from buyers drove the stock to $1.22.

Actively observing the price movement in the last trading, the stock closed the session at $1.13, falling within a range of $1.09 and $1.26. Referring to stock’s 52-week performance, its high was $16.17, and the low was $0.55. On the whole, LABP has fluctuated by 62.58% over the past month.

Top 5 Cheap Stocks to Own Right Now

While finding safe stocks with the potential for monster gains isn't always easy, we've found a few that could pay out well. In fact, within our report, "Top 5 Cheap Stock to Own Right Now", we have identified five stocks we believe could appreciate the most even if you just have $1,000 to invest.

Sign up here to get your free report now. .

Sponsored

With the market capitalization of Landos Biopharma Inc. currently standing at about $51.94 million, investors are eagerly awaiting this quarter’s results, scheduled for Mar 29, 2022 – Apr 04, 2022. As a result, investors might want to see an improvement in the stock’s price before the company announces its earnings report. Analysts are projecting the company’s earnings per share (EPS) to be -$0.33, which is expected to increase to -$0.13 for fiscal year -$1.22 and then to about -$1.11 by fiscal year 2023. Data indicates that the EPS growth is expected to be -19.60% in 2023, while the next year’s EPS growth is forecast to be 9.00%.

Revisions could be a useful indicator to get insight on short-term price movement; so for the company, there were no upward and no downward review(s) in last seven days. We see that LABP’s technical picture suggests that short-term indicators denote the stock is a Hold on average. However, medium term indicators have put the stock in the category of 50% Sell while long term indicators on average have been pointing out that it is a 50% Sell.

The stock’s technical analysis shows that the PEG ratio is about 0, with the price of LABP currently trading nearly 46.85% and 53.97% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 74.85, while the 7-day volatility ratio is showing 15.28% which for the 30-day chart, stands at 11.77%. Furthermore, Landos Biopharma Inc. (LABP)’s average true range (ATR) is 0.10. The company’s stock has been forecasted to trade at an average price of $3.40 over the course of the next 52 weeks, with a low of $0.80 and a high of $6.00. Based on these price targets, the low is 34.43% off current price, whereas the price has to move -391.8% to reach the yearly target high. Additionally, analysts’ median price of $3.40 is likely to be welcomed by investors because it represents a decrease of -178.69% from the current levels.

Data on historical trading for Landos Biopharma Inc. (NASDAQ:LABP) indicates that the trading volumes over the past 10 days have averaged 0.11 million and over the past 3 months, they’ve averaged 106.95K. According to company’s latest data on outstanding shares, there are 40.26 million shares outstanding.

Nearly 24.48% of Landos Biopharma Inc.’s shares belong to company insiders and institutional investors own 63.50% of the company’s shares. The data on short interest also indicates that stock shorts accounted for 0.13 million shares as on Jul 14, 2022, resulting in a short ratio of 1.17. According to the data, the short interest in Landos Biopharma Inc. (LABP) stood at 0.33% of shares outstanding as of Jul 14, 2022; the number of short shares registered in Jun 14, 2022 reached 0.31 million. The stock has fallen by -74.58% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the LABP stock heading into the next quarter.

Leave a Comment

Your email address will not be published.

[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]